Fundraising FoxPathway Bioventures — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.
BiotechDeep TechBoston, US
Shane V. Hegarty(Chief Scientific Officer & Co-Founder)inJoanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)inTiasha Shafiq(Chief of Staff)in
BoardCorey . Goodman(Director)inJonathan Leff(Director)in
Co-investorsSofinnova VenturesvenBio PartnersMRL Ventures FundCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture Partners+8 more
Modifi Bio presents itself as a research-focused biopharmaceutical company developing medicines and vaccines.
BiotechHealthtechNew Haven, US
Ranjit Bindra(Director)inKingson Lin(Cofounder)inKevin L. Rakin(Executive Officer, Director)in
BoardLucas de Breed(Director)Kat Kayser-Bricker(Director)
Co-investorsConnecticut InnovationsHighCape CapitalAdvantage Capital PartnersBrightEdgeIronwood Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.